Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Inventory (2016 - 2026)

Avanos Medical's Inventory history spans 13 years, with the latest figure at $148.0 million for Q4 2025.

  • On a quarterly basis, Inventory rose 6.63% to $148.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $148.0 million, a 6.63% increase, with the full-year FY2025 number at $148.0 million, up 6.63% from a year prior.
  • Inventory hit $148.0 million in Q4 2025 for Avanos Medical, down from $150.6 million in the prior quarter.
  • Over the last five years, Inventory for AVNS hit a ceiling of $200.0 million in Q1 2023 and a floor of $132.3 million in Q4 2022.
  • Historically, Inventory has averaged $158.6 million across 5 years, with a median of $158.8 million in 2021.
  • The widest YoY moves for Inventory: up 26.9% in 2023, down 19.11% in 2023.
  • Tracing AVNS's Inventory over 5 years: stood at $159.3 million in 2021, then dropped by 16.95% to $132.3 million in 2022, then rose by 23.36% to $163.2 million in 2023, then dropped by 14.95% to $138.8 million in 2024, then rose by 6.63% to $148.0 million in 2025.
  • Business Quant data shows Inventory for AVNS at $148.0 million in Q4 2025, $150.6 million in Q3 2025, and $142.7 million in Q2 2025.